Company: RNAC
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001453687-25-000075
Chunk: 52

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 52
---
 for assessing competitive market practices. Compensia undertook a detailed review of the pool of U.S.-based publicly traded companies, taking into consideration our industry and sector, the size of such companies (based on revenues and market capitalization) relative to our size and growth rate, and the following additional factors:

• the company’s stage of clinical development;

• the company’s area(s) of therapeutic focus;

• the company’s market capitalization;

• the comparability of the company’s organizational complexities and growth attributes;

• the comparability of the company’s business focus and corporate strategy; and

• the comparability of the company’s operational performance (for consistency with our strategy and future performance expectations).

Following this review, Compensia recommended to the Compensation Committee the following peer group to consist of 20 publicly traded biotechnology companies, which the Compensation Committee subsequently approved. The selected companies had market capitalizations ranging from approximately $120 million to approximately $1.3 billion, with a median of approximately $347 million. The companies comprising the updated compensation peer group were as follows:

| 4D Molecular Therapeutics |     | Cogent Biosciences        |     | MeiraGTx              |
| Adicet Bio                |     | Editas Medicine           |     | Precigen              |
| Advernum Biotechnologies  |     | Immunic                   |     | REGENXBIO             |
| Allogene Therapeutics     |     | Inovio Pharmaceuticals    |     | Replimune Group       |
| AnaptysBio                |     | iTeos Therapeutics        |     | Sana Biotechnology    |
| Cabaletta Bio             |     | Jasper Therapeutics       |     | Viridian Therapeutics |
| Caribou Biosciences       |     | Lineage Cell Therapeutics |     | Voyager Therapeutics  |

We do not believe that it is appropriate to make compensation decisions, whether regarding base salaries or short-term or long-term incentive compensation, upon any type of benchmarking to a peer or other representative group of companies. The Compensation Committee believes that information regarding the compensation practices at other companies is useful in at least two respects. First, the Compensation Committee recognizes that our compensation policies and practices must be competitive in the marketplace. Second, this information is useful in assessing the reasonableness and appropriateness of individual executive compensation elements and of our overall executive compensation packages. This information is only one of several factors that the Compensation Committee considers, however, in making its decisions